SynthesisBMC gastroenterology2026
Skeletal muscle metastasis from gastric carcinoma: a systematic review of published case reports and case series over six decades.
Synthesis in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSkeletal muscle metastasis (SMM) from gastric carcinoma is exceptionally rare despite the extensive vascularity and mass of skeletal muscles. The true prevalence remains unknown, and existing knowledge is limited to isolated case reports.
objectiveTo systematically review all reported cases of SMM arising from gastric carcinoma, summarize clinical features, diagnostic approaches, imaging characteristics, treatments, and outcomes, and highlight gaps in existing literature.
methodsA comprehensive literature search was conducted across PubMed, Embase, Scopus, and Google Scholar from inception to January 2025, following PRISMA guidelines. All case reports or case series describing biopsy-confirmed skeletal muscle metastasis from gastric carcinoma were included.
resultsA total of 31 fully documented cases were identified from 30 published studies spanning 1960-2025. Patients ranged in age from 30 to 80 years, with a male predominance. Skeletal muscle metastases most commonly involved the thigh, gluteal, paraspinal, and abdominal wall muscles. Patients typically presented with painful, enlarging intramuscular masses that were frequently misdiagnosed as abscesses or soft-tissue sarcomas. Magnetic resonance imaging (MRI) and positron emission tomography-computed tomography (PET-CT) were the most sensitive imaging modalities, while histopathological examination remained the gold standard for diagnosis. Most lesions were associated with poorly differentiated adenocarcinoma or signet-ring cell carcinoma. Survival data were available for 18 of the 31 patients; among these, the mean survival following the diagnosis of skeletal muscle metastasis was 7.7 months, with a median survival of 4.0 months (range, 0.6-30 months), indicating a poor overall prognosis.
conclusionSMM from gastric carcinoma is extremely rare but Despite its rarity, skeletal muscle metastasis should be considered in patients with gastric carcinoma presenting with new painful intramuscular masses, particularly during postoperative surveillance. Early recognition using MRI or PET-CT followed by histopathological confirmation may facilitate timely multidisciplinary management, although the prognosis remains poor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.